Related Experiment Video
Updated: Jun 19, 2026

Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx
Published on: May 2, 2025
Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products
1Department of Medicine, Diabetes Research Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Objective:
RAGE interacts with the endogenous ligands S100 calgranulins and high mobility group box 1 (HMGB1) to induce inflammation. Since hyperglycemia-induced reactive oxygen species (ROS) activate many pathways of diabetic tissue damage, the effect of these ROS on RAGE and RAGE ligand expression was evaluated.
Research Design And Methods:
Expression of RAGE, S100A8, S100A12, and HMGB1 was evaluated in human aortic endothelial cells (HAECs) incubated in normal glucose, high glucose, and high glucose after overexpression of either uncoupling protein 1 (UCP1), superoxide dismutase 2 (SOD2), or glyoxalase 1 (GLO1). Expression was also evaluated in normal glucose after knockdown of GLO1. Expression was next evaluated in high glucose after knockdown of nuclear factor (NF)-kappaB p65 (RAGE) and after knockdown of activated protein-1 (AP-1) (S100A8, S100A12, and HMGB1), and chromatin immunoprecipitation (ChIP) was performed +/- GLO1 overexpression for NFkappaB p65 (RAGE promoter) and AP-1 (S100A8, S100A12, and HMGB1 promoters). Finally, endothelial cells from nondiabetic mice, STZ diabetic mice, and STZ diabetic mice treated with the superoxide dismutase mimetic Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP) were evaluated.
Results:
High glucose increased RAGE, S100A8, S100A12, and HMGB1 expression, which was normalized by overexpression of UCP1, SOD2, or GLO1. GLO1 knockdown mimicked the effect of high glucose, and in high glucose, overexpression of GLO1 normalized increased binding of NFkappaB p65 and AP-1. Diabetes increased RAGE, S100A8, and HMGB1 expression, and MnTBAP treatment normalized this.
Conclusions:
These results show that hyperglycemia-induced ROS production increases expression of RAGE and RAGE ligands. This effect is mediated by ROS-induced methylglyoxal, the major substrate of glyoxalase 1.
Insights
High glucose increases receptor for advanced glycation end products (RAGE) and its ligands via reactive oxygen species (ROS). Glyoxalase 1 (GLO1) mitigates this effect, suggesting a therapeutic target for diabetic complications.
Area of Science:
- Endocrinology and Metabolism
- Cell Biology
- Molecular Biology
Background:
- Receptor for advanced glycation end products (RAGE) interacts with ligands like S100 calgranulins and high mobility group box 1 (HMGB1) to promote inflammation.
- Hyperglycemia-induced reactive oxygen species (ROS) are implicated in diabetic tissue damage pathways.
Purpose of the Study:
- To evaluate the impact of hyperglycemia-induced ROS on RAGE and RAGE ligand expression.
- To investigate the role of glyoxalase 1 (GLO1) in mediating these effects.
Main Methods:
- Assessed expression of RAGE, S100A8, S100A12, and HMGB1 in human aortic endothelial cells (HAECs) under varying glucose conditions and gene manipulations (UCP1, SOD2, GLO1, NF-kappaB p65, AP-1).
- Utilized chromatin immunoprecipitation (ChIP) to examine transcription factor binding.
- Evaluated expression in mouse models of diabetes treated with a superoxide dismutase mimetic (MnTBAP).
Main Results:
- High glucose significantly increased RAGE, S100A8, S100A12, and HMGB1 expression, an effect reversed by UCP1, SOD2, or GLO1 overexpression.
- GLO1 knockdown mimicked high glucose effects; GLO1 overexpression in high glucose normalized NF-kappaB p65 and AP-1 binding.
- Diabetes increased RAGE, S100A8, and HMGB1 expression, which was normalized by MnTBAP treatment.
Conclusions:
- Hyperglycemia-driven ROS production elevates RAGE and RAGE ligand expression.
- Methylglyoxal, a substrate of GLO1, mediates this ROS-induced increase, highlighting GLO1 as a key regulator.
Related Concept Videos
GPCRs Regulate Adenylyl Cylase Activity
Two...
Hyperglycemia
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetic Neuropathy
Type II Diabetes II: Pathophysiology
cAMP-dependent Protein Kinase Pathways